Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,860 questions · 64,864 findings · 4,913 reviews · Headline outcomes only

No studies found 13,869 · 21.4%GRADE not reported 3,491 · 5.4%Very low 16,300 · 25.1%Low 17,338 · 26.7%Moderate 10,900 · 16.8%High 2,966 · 4.6%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Injectional collagenase vs placebo

Outcomes ( · men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees)

The review found no eligible studies for this question.

2 findings from 1 review

Injectional collagenase vs placebo

Patient‐reported ability to have intercourse · men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees)

The review found no eligible studies for this question.

2 findings from 1 review

Injectional collagenase vs placebo

Treatment‐related adverse effects · men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees)

The review found no eligible studies for this question.

2 findings from 1 review

Injectional collagenase vs placebo

Treatment discontinuation · men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees)

The review found no eligible studies for this question.

2 findings from 1 review

Injectional verapamil vs saline (short‐term)

Patient‐reported ability to have intercourse · men with Peyronie's disease (palpable plaque or pain)

It is very uncertain whether injectional verapamil changes patient‐reported ability to have intercourse compared with saline (short‐term) (very low certainty).

1 finding from 1 review

Potassium paraaminobenzoate vs placebo

Treatment‐related adverse effects · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques (pain during…

It is very uncertain whether potassium paraaminobenzoate changes treatment‐related adverse effects compared with placebo (very low certainty).

1 finding from 1 review